文献速递胸部肿瘤

合并症对肺癌筛查死亡率获益的影响:PLCO与NLST试验的事后分析

Impact of Comorbidities on the Mortality Benefits of Lung Cancer Screening: A Post-Hoc Analysis of the PLCO and NLST Trials.
PubMed 文献 · J Thorac Oncol · 2025-01-09

本研究利用PLCO试验数据开发合并症指数(PLCO-ci)预测五年非肺癌死亡率,并在NLST中验证。PLCO-ci在PLCO和NLST的AUC分别为0.72和0.69。NLST中,中等合并症(Q2-Q4)参与者肺癌死亡率显著降低,Q2、Q3、Q4的csHR分别为0.62、0.68、0.72;Q1降低未达统计学显著,Q5无降低。

要点

  • PLCO-ci预测五年非肺癌死亡的AUC在PLCO为0.72,在NLST为0.69。
  • NLST中Q2、Q3、Q4的肺癌死亡风险显著降低,csHR分别为0.62、0.68、0.72。
  • Q2-Q4占60%人群,却贡献了89%的避免肺癌死亡;Q5无死亡率降低。

核心结论

  • 中等合并症个体从肺癌筛查中获益最大,强调需处理合并症以实现肺癌死亡率获益。

研究设计与样本

  • 事后分析,利用PLCO试验符合筛查条件参与者数据(训练集)开发PLCO-ci,并在NLST(验证集)中验证。
  • PLCO-ci采用正则化Cox模型预测五年非肺癌死亡率,性能用ROC曲线下面积评估。
  • NLST中按PLCO-ci五分位(Q1-Q5)比较低剂量CT与胸部X线组的肺癌死亡率,使用病因特异性风险比(csHR)及95%CI。
  • 分析纳入34,690名PLCO参与者和53,452名NLST参与者;平均年龄分别为62岁(±5岁)和61岁(±5岁),男性分别占58%和59%,现吸烟者分别占39%和41%。

主要发现

  • PLCO-ci预测五年非肺癌死亡的AUC在PLCO为0.72(95%CI:0.71-0.74),在NLST为0.69(95%CI:0.67-0.70)。
  • NLST中位随访6.5年,Q2、Q3、Q4的肺癌死亡率显著降低,csHR分别为0.62(95%CI:0.41-0.95)、0.68(95%CI:0.48-0.96)、0.72(95%CI:0.54-0.96)。
  • Q1的肺癌死亡率降低未达统计学显著(csHR=0.72,95%CI:0.45-1.17),Q5无降低(csHR=0.99,95%CI:0.79-1.23)。
  • Q2、Q3、Q4参与者(占60%)贡献了NLST全部避免肺癌死亡的89%。
  • Q1参与者肺癌发病率低,而Q5参与者局部肺癌致死性更高、鳞状细胞癌更多且未治疗肺癌更多。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate how comorbidities affect mortality benefits of lung cancer screening (LCS) with low-dose computed tomography. METHODS: We developed a comorbidity index (Prostate, Lung, Colorectal, and Ovarian comorbidity index [PLCO-ci]) using LCS-eligible participants' data from the Prostate, Lung, Colorectal, and Ovarian (PLCO) trial (training set) and the National Lung Screening Trial (NLST) (validation set). PLCO-ci predicts five-year non-lung cancer (LC) mortality using a regularized Cox model; with performance evaluated using the area under the receiver operating characteristics curve. In NLST, LC mortality (per original publication) was compared between low-dose computed tomography and chest radiograph arms across the PLCO-ci quintile (Q1-5) using a cause-specific hazard ratio (csHR) with 95% confidence intervals (CIs). RESULTS: Analyses included 34,690 PLCO and 53,452 NLST participants (mean age: 62 y [±5 y] and 61 y [±5 y], 58% and 59% male individuals, and 39% and 41% active smokers, respectively). PLCO-ci predicted five-year non-LC mortality with an area under the receiver operating characteristics curve of 0.72 (95% CI: 0.71-0.74) in PLCO and 0.69 (95% CI: 0.67-0.70) in NLST. In NLST, at a median follow-up of 6.5 years, LC mortality was significantly reduced for participants with intermediate comorbidity (Q2, Q3, and Q4): csHR 0.62 (95% CI: 0.41-0.95), 0.68 (95% CI: 0.48-0.96), and 0.72 (95% CI: 0.54-0.96) respectively, with a nonstatistically significant reduction for Q1 (csHR = 0.72, 95% CI: 0.45-1.17) and no reduction for Q5 participants (csHR = 0.99, 95% CI: 0.79-1.23). Participants in Q2, Q3, and Q4 (60%) accounted for 89% of LC deaths averted among all NLST participants. Q1 participants had low LC incidence, whereas Q5 had higher localized LC lethality, more squamous cell carcinomas, and untreated LC. CONCLUSIONS: The PLCO-ci developed in this work shows that individuals with intermediate comorbidity benefited the most from LCS, highlighting the need of addressing comorbidities to achieve LC mortality benefits.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Gendarme S, Irajizad E, Long JP, et al. Impact of Comorbidities on the Mortality Benefits of Lung Cancer Screening: A Post-Hoc Analysis of the PLCO and NLST Trials. J Thorac Oncol. 2025. PMID: 39798695. doi:10.1016/j.jtho.2025.01.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。